• 1
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 2
    Roubey RA. Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 2002; 14: 23842.
  • 3
    De Laat H, Derksen RH, Urbanus RT, De Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 15405.
  • 4
    De Groot PG, Van Lummel M, Pennings M, Urbanus R, Bas Laat de H, Lenting PJ, Derksen RH. Beta2-glycoprotein  I and LDL-receptor family members. Thromb Res 2004; 114: 4559.
  • 5
    Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, Meroni PL. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495500.
  • 6
    Moestrup SK, Schousboe I, Jacobsen C, Moestrup SK, Schousboe I, Jacobsen C, Leheste JR, Christensen EI, Willnow TE. beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J Clin Invest 1998; 102: 9029.
  • 7
    Zhang J, McCrae KR. Annexin  A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005; 105: 19649.
  • 8
    Schousboe I. beta 2-Glycoprotein  I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 108691.
  • 9
    Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakado M, Akino M, Saitou H, Amasaki Y, Jodo S, Amengual O, Koike T. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103: 376672.
  • 10
    Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002; 119: 7818.
  • 11
    Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, Robertson SA, Krilis SA. Impaired thrombin generation in β2-glycoprotein I null mice. J Biol Chem 2001; 276: 1381721.
  • 12
    Riddell DR, Vinogradov DV, Stannard AK, Chadwick N, Owen JS. Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999; 40: 192530.
  • 13
    Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, De Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J Biol Chem 2003; 278: 338318.
  • 14
    Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in the brain. J Biol Chem 1996; 271: 837380.
  • 15
    Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002; 71: 40534.
  • 16
    Kim DH, Magoori K, Inoue TR, Mao CC, Kim HJ, Suzuki H, Fujita T, Endo Y, Saeki S, Yamamoto TT. Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene. J Biol Chem 1997; 272: 8498504.
  • 17
    Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus – comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 91624.
  • 18
    Lutters BCH, Meijers JCM, Derksen RHWM, Arnout J, De Groot PG. Dimers of β2-glycoprotein I mimic the in vitro effects of β2-glycoprotein I-anti-β2-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 30607.
  • 19
    Van Lummel M, Pennings MT, Derksen RH, Urbanus RT, Lutters BC, Kaldenhoven N, De Groot PG. The binding site in β2-glycoprotein I for apoER2′ on platelets is located in domain V. J Biol Chem 2005; 280: 3672936.
  • 20
    Horbach DA, Van Oort E, Tempelman MJ, Derksen RHWM, De Groot PG. The prevalence of a non-phospholipid-binding form of β2-glycoprotein I in human plasma. Consequences for the development of anti-β2-glycoprotein I antibodies. Thromb Haemost 1998; 80: 7917.
  • 21
    Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30: 0E9.
  • 22
    Leahy DJ, Dann III CE, Longo P, Perman B, Ramyar KX. A mammalian expression vector for expression and purification of secreted proteins for structural studies. Protein Expr Purif 2000; 20: 5006.
  • 23
    Neels JG, Van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, Van Zonneveld AJ. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 1999; 274: 3130511.
  • 24
    May P, Herz J, Bock HH. Molecular mechanisms of lipoprotein receptor signalling. Cell Mol Life Sci 2005; 62: 232538.
  • 25
    Melman L, Cao ZF, Rennke S, Marzolo MP, Wardell MR, Bu G. High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs. J Biol Chem 2001; 276: 2933846.
  • 26
    Raffai R, Weisgraber KH, MacKenzie R, Rupp B, Rassart E, Hirama T, Innerarity TL, Milne R. Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. Studies using site-directed mutagenesis and molecular modeling. J Biol Chem 2000; 275: 710916.
  • 27
    Guerin J, Sheng Y, Reddel S, Iverson GM, Chapman MG, Krilis SA. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002; 277: 26449.
  • 28
    Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High-affinity binding of beta2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275; 155418.
  • 29
    Zhou H, Roubey RAS. Annexin  A2 and the upregulation of monocyte tissue factor activity by aPL. Lupus 2002; 11: 543.
  • 30
    Satta N, Dunoyer-Geindre S, Fish RJ, Reber G, Boehlen F, Kruithof EKO, De Moerloose P. The activation of mouse fibroblasts by antiphospholipid antibodies requires TLR2. J Thromb Haemost 2005; 3: 1223.
  • 31
    Meroni PL, Raschi E, Testoni C, Parisio A, Borghi MO. Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 2004; 3; 51015.
  • 32
    Pennings MTT, Derksen RHWM, Van Lummel M, Adelmeijer J, Lisman T, De Groot PG. Platelet adhesion to dimeric beta2-glycoprotein I under conditions of flow is mediated by glycoprotein Ib. J Thromb Haemost 2005; 3: 256.
  • 33
    De Groot PG, Derksen RH. The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Curr Opin Infect Dis 2005; 18: 20510.
  • 34
    Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 102839.
  • 35
    Vasoo S, Sangle S, Zain M, D'Cruz D, Hughes G. Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome. Lupus 2005; 14: 33945.
  • 36
    D'Cruz DP. Renal manifestations of the antiphospholipid syndrome. Lupus 2005; 14: 458.
  • 37
    Antunes MC, D'Cruz D, Hughes GR. Neurological manifestations of anti-phospholipid (Hughes) syndrome. Clin Exp Rheumatol 2004; 22: 7715.
  • 38
    Suarez AL, Hughes GR, Khamashta MA. Neurological manifestations of the antiphospholipid syndrome. Med Clin (Barc.) 2005; 124: 6303.
  • 39
    Dayal NA, Isenberg DA. Endstage renal failure in primary antiphospholipid syndrome – case report and review of literature. Rheumatology (Oxford) 2003; 42: 11289.
  • 40
    Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, Shoenfeld Y. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005; 210: 74954.
  • 41
    Mayer H, Duit S, Hauser C, Schneider WJ, Nimpf J. Reconstitution of the reelin signaling pathway in fibroblasts demonstrates that Dab1 phosphorylation is independent of receptor localization in lipid rafts. Mol Cell Biol 2006; 26: 1927.
  • 42
    Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost 2005; 3: 188493.
  • 43
    Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem 2004; 279: 3430210.